“…The current first-line treatment of CIDP includes intravenous immunoglobulin (IVIG), corticosteroids, and plasma exchange (PE) ( 1 , 2 , 27 ), and now, subcutaneous immunoglobulin (SCIG) has been gradually used for the maintenance treatment of CIDP patients who respond well to IVIG due to its similar efficacy and convenience, reducing infusion-related side effects ( 28 , 29 ). However, more than 20% of patients do not respond to standard therapies, other biological agents, or immunosuppressive agents such as azathioprine, cyclophosphamide, ciclosporin, mycophenolate mofetil, and rituximab, which can be used as a secondary therapy when the first-line treatment was not effective or tolerated ( 1 , 2 , 10 , 12 ).…”